JP5306387B2 - イバブラジンおよび薬学的に許容され得る酸とのその付加塩の新規な合成法 - Google Patents
イバブラジンおよび薬学的に許容され得る酸とのその付加塩の新規な合成法 Download PDFInfo
- Publication number
- JP5306387B2 JP5306387B2 JP2011030786A JP2011030786A JP5306387B2 JP 5306387 B2 JP5306387 B2 JP 5306387B2 JP 2011030786 A JP2011030786 A JP 2011030786A JP 2011030786 A JP2011030786 A JP 2011030786A JP 5306387 B2 JP5306387 B2 JP 5306387B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- acid
- compound
- viii
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003825 ivabradine Drugs 0.000 title claims description 12
- 239000002253 acid Substances 0.000 title claims description 7
- 150000003839 salts Chemical class 0.000 title claims description 7
- 230000015572 biosynthetic process Effects 0.000 title claims description 5
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 title claims description 5
- 238000003786 synthesis reaction Methods 0.000 title claims description 5
- 150000007513 acids Chemical class 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000001308 synthesis method Methods 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- UAWABSHMGXMCRK-UHFFFAOYSA-L samarium(ii) iodide Chemical compound I[Sm]I UAWABSHMGXMCRK-UHFFFAOYSA-L 0.000 claims description 4
- 150000003573 thiols Chemical class 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 239000007868 Raney catalyst Substances 0.000 claims description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 3
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 239000002841 Lewis acid Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 150000007517 lewis acids Chemical class 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 229940107700 pyruvic acid Drugs 0.000 claims description 2
- 238000006722 reduction reaction Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 2
- HLUKNZUABFFNQS-ZMBIFBSDSA-N ivabradine hydrochloride Chemical compound Cl.C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 HLUKNZUABFFNQS-ZMBIFBSDSA-N 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- HKGVPFUXFNPQET-OAQYLSRUSA-N n-[3-[[(7s)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-n-[2-(3,4-dimethoxyphenyl)ethyl]-2-hydroxyacetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C(=O)CO)CCCN(C)C[C@@H]1C2=CC(OC)=C(OC)C=C2C1 HKGVPFUXFNPQET-OAQYLSRUSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- -1 t-Butyl [2- (3,4-dimethoxyphenyl) ethyl] carbamate Di-t-butyl dicarbonate Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HZDNNJABYXNPPV-UHFFFAOYSA-N (2-chloro-2-oxoethyl) acetate Chemical compound CC(=O)OCC(Cl)=O HZDNNJABYXNPPV-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 230000000059 bradycardiac effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229960000504 ivabradine hydrochloride Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- SOHCYNFHNYKSTM-UHFFFAOYSA-N methylsulfinylmethane;oxolane Chemical compound CS(C)=O.C1CCOC1 SOHCYNFHNYKSTM-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- HKGKWPHTZIKZLN-HXUWFJFHSA-N n'-[[(7s)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl]-n-[2-(3,4-dimethoxyphenyl)ethyl]-n'-methylpropane-1,3-diamine Chemical compound C1=C(OC)C(OC)=CC=C1CCNCCCN(C)C[C@@H]1C2=CC(OC)=C(OC)C=C2C1 HKGKWPHTZIKZLN-HXUWFJFHSA-N 0.000 description 1
- QLXKSMQGYNTVJJ-OAQYLSRUSA-N n-[3-[[(7s)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-n-[2-(3,4-dimethoxyphenyl)ethyl]-2-oxoacetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C(=O)C=O)CCCN(C)C[C@@H]1C2=CC(OC)=C(OC)C=C2C1 QLXKSMQGYNTVJJ-OAQYLSRUSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/06—One of the condensed rings being a six-membered aromatic ring the other ring being four-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
で示されるイバブラジンまたは3−{3−[{[(7S)−3,4−ジメトキシビシクロ[4.2.0]オクタ−1,3,5−トリエン−7−イル]メチル}(メチル)アミノ]プロピル}−7,8−ジメトキシ−1,3,4,5−テトラヒドロ−2H−3−ベンゾアゼピン−2−オン、薬学的に許容され得る酸とのその付加塩、およびその水和物の合成方法に関するものである。
[式中、Rは、置換または非置換の、場合によりペルフッ素化された、直鎖もしくは分枝鎖アルキル基、置換または非置換のアリール基、置換または非置換のベンジル基、あるいは基CH2CO2Etを表す]
で示されるヘミチオアセタールを形成して、これを環化反応に付して、式(VIII):
[式中、Rは、上記に定義されたとおりである]
で示される化合物を得て、これを還元反応に付して、式(I)のイバブラジンを得て、これを場合により、塩酸、臭化水素酸、硫酸、リン酸、酢酸、トリフルオロ酢酸、乳酸、ピルビン酸、マロン酸、コハク酸、グルタル酸、フマル酸、酒石酸、マレイン酸、クエン酸、アスコルビン酸、シュウ酸、メタンスルホン酸、ベンゼンスルホン酸およびショウノウ酸から選ばれる薬学的に許容され得る酸とのその付加塩、ならびにその水和物に変換してもよいことを特徴とする方法に関するものである。
DMF:N,N−ジメチルホルムアミド
DMSO:ジメチルスルホキシド
THF:テトラヒドロフラン
IR:赤外線
二炭酸ジ−t−ブチル(12g;55.2mmol)を、ジクロロメタン(200ml)中の2−(3,4−ジメトキシフェニル)エチルアミン(10g;55.2mmol)の溶液に加えた。環境温度で1時間接触させた後、反応混合物を減圧下で濃縮した。残渣をペンタン(100ml)に溶解し、環境温度で1時間接触させた後、懸濁液をフリット越しにろ過した。標記生成物13.2gを固体の形態で得た。
収量=85%
融点=65±2℃
DMF40ml中の上記工程で得た化合物(7.6g;27mmol)の溶液に、NaH(油中60%)(1.14g;28.5mmol)を環境温度で小分けして加えた。環境温度で1時間接触させた後、DMF16ml中の3−クロロ−N−{[(7S)−3,4−ジメトキシビシクロ[4.2.0]オクタ−1,3,5−トリエン−7−イル]メチル}−N−メチル−1−プロパンアミン(7.68g;27mmol)の溶液を加え、次いで、反応混合物を80℃に3時間加熱した。環境温度に冷却した後、反応混合物を蒸留水および氷の混合物に注ぎ込んだ。水相を酢酸エチルで抽出した。併せた有機相を、MgSO4で乾燥し、次いで減圧下で濃縮した。残渣をシリカでのクロマトグラフィー(CH2Cl2/EtOH:95/5)によって精製し、標記生成物9.1gを油状物の形態で得た。
収量=64%
IR:ν=3340、1678、1519、1167cm−1。
上記工程で得た化合物9g(17mmol)を2.8NHClエタノール溶液に溶解した。環境温度で2時間接触させた後、反応混合物を減圧下で濃縮した。残渣を1N水酸化ナトリウム溶液に溶解し、次いで、水相を酢酸エチルで抽出した。有機相をMgSO4で乾燥し、次いで減圧下で濃縮した後、標記生成物6.8gを油状物の形態で得た。
収量=93%
IR:ν=3304、2793、1261、1236、1205、1153cm−1。
工程1:酢酸2−{{3−[{[(7S)−3,4−ジメトキシビシクロ[4.2.0]オクタ−1,3,5−トリエン−7−イル]メチル}(メチル)アミノ]プロピル}−[2−(3,4−ジメトキシフェニル)エチル]アミノ}−2−オキソエチル
ジクロロメタン200ml中の上記工程で得た化合物(6.8g;15.8mmol)の溶液に、0℃でトリエチルアミン(3.1g;22mmol)を加え、次いで、塩化アセトキシアセチル(2.1ml;19mmol)を滴加した。環境温度で0.5時間接触させた後、反応混合物を蒸留水で洗浄し、次いで、有機相をMgSO4で乾燥した。有機相を減圧下で濃縮した後、標記生成物8gを油状物の形態で得て、精製せずに次工程で用いた。
水/メタノール混合物(2/1)80ml中の上記工程で得た化合物(8g)の溶液に、K2CO3(8.3g;60.4mmol)を加えた。環境温度で1時間接触させた後、反応混合物を減圧下で濃縮し、次いで、残渣を蒸留水に溶解した。酢酸エチルで抽出した後、併せた有機相を、MgSO4で乾燥し、次いで減圧下で濃縮した。標記生成物6.2gを油状物の形態で得た。
収量=81%(2工程で)
IR:ν=3406、2794、1641、1261、1236、1205、1153cm−1。
ジクロロメタン25ml中の塩化オキサリル(0.6ml;6.77mmol)の溶液に、ジクロロメタン5ml中のDMSO(0.9ml;12.32mmol)の溶液を−78℃で加えた。−78℃で1時間接触させた後、ジクロロメタン25ml中の上記工程で得た化合物(3g;6.16mmol)の溶液を0.5時間にわたって加えた。−78℃で1時間接触させた後、トリエチルアミン(4.3ml;30.8mmol)を加え、次いで、反応混合物を、環境温度で3時間攪拌し、次いで飽和NaHCO3水溶液に注ぎ込んだ。有機相を、MgSO4で乾燥し、次いで減圧下で濃縮した。標記生成物2.7gを油状物の形態で得た。
収量=89%
IR:ν=2788、1645、1589、1261、1236、1207、1151cm−1。
ジクロロメタン60ml中の上記工程で得た化合物(2.6g;5.17mmol)の溶液に、チオフェノール(0.53ml;5.17mmol)を加えた。環境温度で一晩接触させた後、無水トリフルオロ酢酸(6.5ml;47mmol)、次いでBF3・OEt2(6.5ml;26mmol)を逐次加えた。反応混合物を、環境温度で3時間攪拌し、次いで飽和NaHCO3水溶液に注ぎ込んだ。有機相をMgSO4で乾燥し、次いで減圧下で濃縮した後に得られた残渣を、シリカでのクロマトグラフィー(CH2Cl2/EtOH/28%NH4OH:97/3/0.3)によって精製した。標記生成物1.15gを油状物の形態で得た。
収量=38%
IR:ν=2790、1641、1245、1205、1174cm−1。
エタノール中の上記工程で得た化合物(0.8g;1.39mmol)の溶液に、ラネーニッケル(2.5g)(H2O中50%)を加えた。還流にて1時間接触させた後、懸濁液を冷却し、次いでセライト越しにろ過した。標記生成物600mgを油状物の形態で得た。
収量=94%
IR:ν=2788、1646、1519、1461、1245、1105cm−1。
上記工程で得た生成物から出発し、欧州特許出願公開第0 534 859号公報(EP 0 534 859)に記載された手順(実施例2、工程E)に従って、標記生成物を製造した。
Claims (11)
- 式(I):
で示されるイバブラジンの合成方法であって、式(VI):
で示される化合物を、有機溶媒中でチオールの作用に付して、式(VII):
[式中、Rは、置換または非置換の、場合によりペルフッ素化された、直鎖もしくは分枝鎖アルキル基、置換または非置換のアリール基、置換または非置換のベンジル基、あるいは基CH2CO2Etを表す]
で示されるヘミチオアセタールを形成して、これを環化反応に付して、式(VIII):
[式中、Rは、上記に定義されたとおりである]
で示される化合物を得て、これを、還元反応に付して、式(I)のイバブラジンを得て、これを、場合により、塩酸、臭化水素酸、硫酸、リン酸、酢酸、トリフルオロ酢酸、乳酸、ピルビン酸、マロン酸、コハク酸、グルタル酸、フマル酸、酒石酸、マレイン酸、クエン酸、アスコルビン酸、シュウ酸、メタンスルホン酸、ベンゼンスルホン酸およびショウノウ酸から選ばれる薬学的に許容され得る酸とのその付加塩、ならびにその水和物に変換してもよいことを特徴とする方法。 - 式(VII)のヘミチオアセタールを形成する反応に用いられる有機溶媒がジクロロメタンであることを特徴とする、請求項1記載の合成方法。
- 式(VI)の化合物と反応させるチオールがチオフェノールであることを特徴とする、請求項1または2のいずれかに記載の合成方法。
- 式(VII)の化合物を環化して式(VIII)の化合物を形成する反応に用いられる溶媒がジクロロメタンであることを特徴とする、請求項1〜3のいずれか一項に記載の合成方法。
- 式(VII)の化合物を環化して式(VIII)の化合物を形成する反応を、無水酢酸、無水トリフルオロ酢酸およびトリフルオロメタンスルホン酸トリメチルシリルから選ばれる試薬の存在下で実施することを特徴とする、請求項1〜4のいずれか一項に記載の合成方法。
- 式(VII)の化合物を環化して式(VIII)の化合物を形成する反応を、無水トリフルオロ酢酸の存在下で実施することを特徴とする、請求項5記載の合成方法。
- 式(VII)の化合物を環化して式(VIII)の化合物を形成する反応を、無水トリフルオロ酢酸、ならびにBF3・OEt2、Sc(OTf)3およびYb(OTf)3から選ばれるルイス酸の存在下で実施することを特徴とする、請求項6記載の合成方法。
- 式(VII)の化合物を環化して式(VIII)の化合物を形成する反応を、無水トリフルオロ酢酸およびBF3・OEt2の存在下で実施することを特徴とする、請求項7記載の合成方法。
- 式(VIII)の化合物を還元する反応を、エタノール中のラネーニッケルの存在下、またはテトラヒドロフラン中のヨウ化サマリウム(II)の存在下で実施することを特徴とする、請求項1〜8のいずれか一項に記載の合成方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR10/00657 | 2010-02-17 | ||
FR1000657A FR2956401B1 (fr) | 2010-02-17 | 2010-02-17 | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011168590A JP2011168590A (ja) | 2011-09-01 |
JP5306387B2 true JP5306387B2 (ja) | 2013-10-02 |
Family
ID=42133409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011030786A Active JP5306387B2 (ja) | 2010-02-17 | 2011-02-16 | イバブラジンおよび薬学的に許容され得る酸とのその付加塩の新規な合成法 |
Country Status (36)
Country | Link |
---|---|
US (1) | US8278440B2 (ja) |
EP (1) | EP2364972B1 (ja) |
JP (1) | JP5306387B2 (ja) |
KR (1) | KR101310683B1 (ja) |
CN (3) | CN103265491B (ja) |
AR (1) | AR080178A1 (ja) |
AU (1) | AU2011200403B2 (ja) |
BR (1) | BRPI1100169A2 (ja) |
CA (1) | CA2731315C (ja) |
CL (1) | CL2011000297A1 (ja) |
CY (1) | CY1113338T1 (ja) |
DK (1) | DK2364972T3 (ja) |
EA (1) | EA019373B1 (ja) |
ES (1) | ES2396042T3 (ja) |
FR (1) | FR2956401B1 (ja) |
GE (1) | GEP20135737B (ja) |
HK (3) | HK1162021A1 (ja) |
HR (1) | HRP20120955T1 (ja) |
JO (1) | JO2854B1 (ja) |
MA (1) | MA32681B1 (ja) |
ME (1) | ME01464B (ja) |
MX (1) | MX2011001465A (ja) |
MY (1) | MY147697A (ja) |
NZ (1) | NZ590883A (ja) |
PE (1) | PE20120576A1 (ja) |
PL (1) | PL2364972T3 (ja) |
PT (1) | PT2364972E (ja) |
RS (1) | RS52529B (ja) |
SA (1) | SA111320199B1 (ja) |
SG (1) | SG173961A1 (ja) |
SI (1) | SI2364972T1 (ja) |
TW (1) | TWI395738B (ja) |
UA (1) | UA106208C2 (ja) |
UY (1) | UY33211A (ja) |
WO (1) | WO2011101558A1 (ja) |
ZA (1) | ZA201100964B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2950343B1 (fr) * | 2009-09-18 | 2011-11-18 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
CN102566619B (zh) * | 2012-02-07 | 2013-12-25 | 宁波市镇海华泰电器厂 | 噪声式水温控制装置 |
FR2988720B1 (fr) * | 2012-03-27 | 2014-03-14 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
CN103848789B (zh) * | 2012-11-29 | 2016-05-18 | 江苏恒瑞医药股份有限公司 | 一种伊伐布雷定的制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3119874A1 (de) * | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
FR2681862B1 (fr) | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
AU2003239508A1 (en) * | 2002-05-21 | 2003-12-12 | Bristol-Myers Squibb Company | Indole compounds useful as impdh inhibitors |
FR2868775B1 (fr) * | 2004-04-13 | 2008-04-11 | Servier Lab | Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2868776B1 (fr) * | 2004-04-13 | 2008-04-18 | Servier Lab | Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
TW200817334A (en) * | 2005-02-07 | 2008-04-16 | Servier Lab | New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid |
EP2097383B1 (en) * | 2006-11-30 | 2012-02-08 | Cadila Healthcare Limited | Process for preparation of ivabradine hydrochloride |
CN101284813B (zh) * | 2007-04-12 | 2012-08-15 | 上海优拓医药科技有限公司 | 伊伐布雷定的制备方法 |
ES2528026T3 (es) * | 2007-05-30 | 2015-02-03 | Ind-Swift Laboratories Limited | Sales de oxalato de ivabridina cristalino y polimorfos de los mismos |
CN101544605A (zh) * | 2008-03-24 | 2009-09-30 | 北京深蓝海生物医药科技有限公司 | 伊伐布雷定及其药学上可接受的加成盐的制备方法 |
FR2932800B1 (fr) | 2008-06-20 | 2015-02-20 | Servier Lab | Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
ES2402765T3 (es) | 2008-12-22 | 2013-05-08 | Krka, D.D., Novo Mesto | Procedimiento de preparación de ivabradina |
-
2010
- 2010-02-17 FR FR1000657A patent/FR2956401B1/fr not_active Expired - Fee Related
-
2011
- 2011-01-30 JO JO201130A patent/JO2854B1/en active
- 2011-01-31 AU AU2011200403A patent/AU2011200403B2/en not_active Ceased
- 2011-01-31 UY UY33211A patent/UY33211A/es unknown
- 2011-01-31 SG SG2011006848A patent/SG173961A1/en unknown
- 2011-01-31 PE PE2011000106A patent/PE20120576A1/es active IP Right Grant
- 2011-01-31 MY MYPI2011000487A patent/MY147697A/en unknown
- 2011-02-02 NZ NZ590883A patent/NZ590883A/en not_active IP Right Cessation
- 2011-02-07 ZA ZA2011/00964A patent/ZA201100964B/en unknown
- 2011-02-08 MX MX2011001465A patent/MX2011001465A/es active IP Right Grant
- 2011-02-09 CA CA2731315A patent/CA2731315C/fr not_active Expired - Fee Related
- 2011-02-11 CL CL2011000297A patent/CL2011000297A1/es unknown
- 2011-02-14 UA UAA201101721A patent/UA106208C2/ru unknown
- 2011-02-15 EA EA201100230A patent/EA019373B1/ru not_active IP Right Cessation
- 2011-02-15 MA MA33624A patent/MA32681B1/fr unknown
- 2011-02-15 GE GEAP201112105A patent/GEP20135737B/en unknown
- 2011-02-15 AR ARP110100451A patent/AR080178A1/es unknown
- 2011-02-15 US US12/931,961 patent/US8278440B2/en not_active Expired - Fee Related
- 2011-02-16 PT PT11290091T patent/PT2364972E/pt unknown
- 2011-02-16 DK DK11290091.5T patent/DK2364972T3/da active
- 2011-02-16 SA SA111320199A patent/SA111320199B1/ar unknown
- 2011-02-16 CN CN201310167930.1A patent/CN103265491B/zh not_active Expired - Fee Related
- 2011-02-16 CN CN201110038835.2A patent/CN102161642B/zh not_active Expired - Fee Related
- 2011-02-16 RS RS20120511A patent/RS52529B/en unknown
- 2011-02-16 ES ES11290091T patent/ES2396042T3/es active Active
- 2011-02-16 TW TW100105145A patent/TWI395738B/zh not_active IP Right Cessation
- 2011-02-16 SI SI201130005T patent/SI2364972T1/sl unknown
- 2011-02-16 EP EP11290091A patent/EP2364972B1/fr active Active
- 2011-02-16 CN CN201310168300.6A patent/CN103232360B/zh not_active Expired - Fee Related
- 2011-02-16 ME MEP-2012-139A patent/ME01464B/me unknown
- 2011-02-16 WO PCT/FR2011/000092 patent/WO2011101558A1/fr active Application Filing
- 2011-02-16 PL PL11290091T patent/PL2364972T3/pl unknown
- 2011-02-16 JP JP2011030786A patent/JP5306387B2/ja active Active
- 2011-02-16 BR BRPI1100169-0A patent/BRPI1100169A2/pt not_active Application Discontinuation
- 2011-02-17 KR KR1020110014201A patent/KR101310683B1/ko active IP Right Grant
-
2012
- 2012-02-23 HK HK12101805.9A patent/HK1162021A1/xx not_active IP Right Cessation
- 2012-11-13 CY CY20121101086T patent/CY1113338T1/el unknown
- 2012-11-21 HR HRP20120955AT patent/HRP20120955T1/hr unknown
-
2013
- 2013-09-16 HK HK13110667.6A patent/HK1183295A1/xx not_active IP Right Cessation
- 2013-09-25 HK HK13110938.9A patent/HK1183488A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5563600B2 (ja) | イバブラジン及びその薬学的に許容しうる酸付加塩の新規の合成方法 | |
CA2697563C (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
JP5306387B2 (ja) | イバブラジンおよび薬学的に許容され得る酸とのその付加塩の新規な合成法 | |
JP2013505225A (ja) | イバブラジン及び薬学的に許容しうる酸とのその付加塩の新規な合成方法 | |
TWI419879B (zh) | 合成依伐布雷定(ivabradine)及其醫藥上可接受酸之加成鹽之新穎方法 | |
WO2012110716A1 (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
TWI500596B (zh) | 合成3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-甲腈之方法,及於合成依伐布雷定(ivabradine)及其與醫藥上可接受酸之加成鹽之應用 | |
JP5732159B2 (ja) | 7,8−ジメトキシ−1,3−ジヒドロ−2h−3−ベンゾアゼピン−2−オン化合物の合成方法及びイバブラジンの合成における適用 | |
JP2014080421A (ja) | 3−(2−ブロモ−4,5−ジメトキシフェニル)プロパンニトリルの新規合成方法、及びイバブラジン及び薬学的に許容される酸とのその付加塩の合成における適用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110329 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130416 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130521 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130618 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130625 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5306387 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |